Corvus Pharmaceuticals, Inc. Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-based Payment Arrangement, Percent
Corvus Pharmaceuticals, Inc. (CRVS) reported Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-based Payment Arrangement, Percent of -1.00% for the 12-month period ending 2023-12-31, per its 10-K filed 2025-03-25.
Financial Statements › Notes › Income Taxes
us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent · last filed 2025-03-25
- Corvus Pharmaceuticals, Inc. effective income tax rate reconciliation, tax expense (benefit), share-based payment arrangement, percent for fiscal 2023 was -1.00%.
- Corvus Pharmaceuticals, Inc. effective income tax rate reconciliation, tax expense (benefit), share-based payment arrangement, percent for fiscal 2022 was -1.00%.
- Corvus Pharmaceuticals, Inc. effective income tax rate reconciliation, tax expense (benefit), share-based payment arrangement, percent for fiscal 2021 was -1.00%.
- Corvus Pharmaceuticals, Inc. effective income tax rate reconciliation, tax expense (benefit), share-based payment arrangement, percent for fiscal 2020 was -10.00%.
| Period end | Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-based Payment Arrangement, Percent 12 month | Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-based Payment Arrangement, Percent 12 month as first filed |
|---|---|---|
| 2023-12-31 | -1.00% 10-K · filed 2025-03-25 | |
| 2022-12-31 | -1.00% 10-K · filed 2025-03-25 | |
| 2021-12-31 | -1.00% 10-K · filed 2024-03-19 | |
| 2020-12-31 | -10.00% 10-K · filed 2023-03-28 | -34.00% 10-K · filed 2021-03-25 |
| 2019-12-31 | -1.00% 10-K · filed 2022-03-10 | |
| 2018-12-31 | -1.00% 10-K · filed 2021-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Apnimed, Inc. (APMD) | United States | $0.899B |